CAS NO: | 219861-08-2 |
规格: | ≥98% |
包装 | 价格(元) |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
2g | 电议 |
5g | 电议 |
Molecular Weight (MW) | 414.43 |
---|---|
Formula | C20H21FN2O.C2H2O4 |
CAS No. | 219861-08-2 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 83 mg/mL (200.3 mM) |
Water: 25 mg/mL (60.3 mM) | |
Ethanol: <1 mg/mL | |
Other info | Chemical Name: (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;oxalic acid InChi Key: KTGRHKOEFSJQNS-BDQAORGHSA-N InChi Code: InChI=1S/C20H21FN2O.C2H2O4/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;3-1(4)2(5)6/h4-9,12H,3,10-11,14H2,1-2H3;(H,3,4)(H,5,6)/t20-;/m0./s1 SMILES Code: CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O |
Synonyms | Lu-10-171; Escitalopram Oxalate; Cipralex; Lexapro; (S)-Citalopram Oxalate; Lu10171; Lu 10171; UNII-5U85DBW7LO; Citalopram;Cytalopram; Escitalopram Lexapro |
In Vitro | In vitro activity: Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram is found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase. |
---|---|
In Vivo | |
Animal model | |
Formulation & Dosage | |
References | Encephale. 2007 Dec;33(6):965-72; J Med Chem. 2010 Aug 26;53(16):6112-21. |